Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CLEC2D + toll-like receptor 9 agonist
- Development stage
- Preclinical
- Lead developer
- Immunitas Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-CLEC2D + toll-like receptor 9 agonist conjugate is an immune stimulating antibody complex (ISAC) being developed by Immunitas Therapeutics. It consists of a fully human monoclonal antibody targeting CLEC2D (C-type lectin domain family 2 member D) conjugated to a CpG oligonucleotide, which serves as a Toll-like receptor 9 (TLR9) agonist. This therapeutic approach leverages CLEC2D-mediated internalization to deliver the CpG payload specifically into myeloid cells, B cells, and plasmacytoid dendritic cells. By triggering the TLR9 pathway locally within the tumor microenvironment, the conjugate stimulates inflammatory responses and enables the induction of sustained T cell and NK cell immunity. The program is currently in the research and preclinical stage for oncology indications, with proof-of-concept data presented at SITC 2023.
- Other names
- Anti CLEC2D-TLR9 agonist conjugateanti-CLEC2D–TLR9 conjugateImmunitas CLEC2D-TLR9 ISAC
02
Targets
TLR9 (Toll-like receptor 9)CLEC2D (Lectin-like transcript 1)
Beyond the preview
Go deeper on anti-CLEC2D + toll-like receptor 9 agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CLEC2D + toll-like receptor 9 agonist.